This is a Phase 4 Clinical Trial. Novavax, Inc. (Novavax) is sponsoring this study, and it will take place at up to 90 study sites in the United States (US), with about 6,500 people participating. This research study is being conducted to see if the study vaccine (NVX-CoV2705) prevents COVID-19 and to provide additional information on the safety of the study vaccine in healthy adults between 50 to 64 years old.
The study vaccine is the same one available at the pharmacy this season. For this study, each person will receive a single dose of either study vaccine or placebo (a saline injection that does not contain any active ingredients). Study participants will be assigned randomly (by chance, like flipping a coin) to get either the study vaccine or placebo with about 3,250 people receiving study vaccine and 3,250 people receiving placebo. Each participant has a 50/50 (equal chance) of being assigned to either study treatment.
Study participant will be required to complete eDiary on a downloaded App to record COVID-19 Symptoms if any.
- Day 0 - Screening and Vaccination - In Person Visit
- Day 42, Day 90, Day 180 - Telephone Follow up
- Illness Visit - In person